A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Squamous Cell
  • Cisplatin
  • Head and Neck Neoplasms
  • Radiotherapy, Intensity-Modulated

abstract

  • The addition of bevacizumab to high-dose cisplatin plus IMRT did not appear to increase toxicity to unacceptable levels among patients with HNSCC, and the efficacy results were encouraging.

publication date

  • October 15, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.27498

PubMed ID

  • 22415650

Additional Document Info

start page

  • 5008

end page

  • 14

volume

  • 118

number

  • 20